Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PHARMACEUTICALS INC Form 4 November 30, 2015 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person <u>*</u> HARRIGAN EDMUND			Symbo	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(Last)	(First)		of Earliest T	Fransaction	Director Officer (gi		% Owner her (specify		
3611 VALLEY CENTRE DRIVE,			· ·	(Month/Day/Year) 11/25/2015			below) below)			
	SUITE 300		, 11,20							
(Street)				mendment, D	Date Original	6. Individual or	Joint/Group Fili	ng(Check		
	SAN DIEG	O, CA 92130	Filed(N	Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
	(City)	(State)	(Zin)							
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Own										
	1.Title of	2. Transaction Date		3.	4. Securities	5. Amount of	6. Ownership	7. Nature of		
	Security	(Month/Day/Year)	Execution Date, if		onAcquired (A) or	Securities	Form: Direct	Indirect		
	(Instr. 3)		any	Code	Disposed of (D)	Beneficially	(D) or Indirect			
			(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)	Owned Following	(I) (Instr. 4)	Ownership (Instr. 4)		
						Reported	(1130.7)	(1150. 7)		
					(A)	1				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Transaction(s)

(Instr. 3 and 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	Γ

(A)

or

Code V Amount (D) Price

Г

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Security (Instr. 3)			any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (or Dispose (D) (Instr. 3, 4, and 5)	(A) sed of		'Year)	(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 38.28	11/25/2015		А	15,000		<u>(1)</u>	11/24/2025	Common Stock	15,000
Reporting Owners										
Reporting Owner Name / Address Directo				ationships wner Off	ïcer	Other				

HARRIGAN EDMUND 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130

Signatures

/s/ Glenn F. Baity, Attorney-in-Fact 11/30/2015

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) $\frac{50\%}{\text{grant.}}$ of the shares subject to the Stock Option vest and become exercisable on each of the first and second anniversary of the date of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S ()